Laurus Labs Limited reported a strong growth in profitability for the quarter ended March 31, 2026, supported by steady revenue expansion and improved operating performance. The company’s revenue from operations rose 5.31% year-on-year (YoY) to ₹1,811.57 crore, while profit attributable to equity holders increased 19.37% YoY to ₹279.14 crore.
Total income stood at ₹1,823.37 crore compared to ₹1,778.87 crore in the corresponding quarter last year. Total expenses declined marginally to ₹1,462.00 crore from ₹1,466.53 crore, reflecting improved cost control despite higher employee and other operating expenses.
At the operating level, EBITDA came in at ₹512.11 crore for the quarter, compared to ₹420.60 crore in the year-ago period, marking a growth of 21.76%. EBITDA margin improved to 28.27% from 24.45% in the corresponding quarter last year, indicating a healthy expansion of 382 basis points.
Finance costs declined to ₹40.44 crore from ₹56.40 crore, while depreciation and amortisation expense increased to ₹122.10 crore from ₹110.43 crore.
Profit after tax stood at ₹281.91 crore compared to ₹233.87 crore a year ago. Earnings per share (EPS) rose to ₹5.17 from ₹4.34 in the year-ago quarter, reflecting a growth of 19.12%.
Laurus Labs is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), formulations, and synthesis services.
The Board of Directors approved the payment of a second interim dividend of ₹1.20 per equity share (60% of face value ₹2 each) for the financial year 2025–26. The company has fixed May 8, 2026, as the record date to determine shareholder eligibility, and the dividend will be paid on or after May 20, 2026.
Overall, the company delivered a strong performance in the March quarter, with growth in both revenue and profitability, supported by improved operating efficiency and margin expansion.